Exagen (NASDAQ:XGN) Stock Price Breaks Below 200 Day Moving Average After Earnings Miss

Exagen Inc. (NASDAQ:XGN – Get Free Report) crossed below its two hundred day moving average during trading on Wednesday following a dissappointing earnings announcement. The stock has a two hundred day moving average of $5.13 and traded as low as $4.69. Exagen shares last traded at $5.03, with a volume of 1,204,145 shares trading hands.

The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $18.42 million during the quarter, compared to the consensus estimate of $18.34 million. Exagen had a negative return on equity of 125.60% and a negative net margin of 25.14%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on XGN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Exagen in a research note on Wednesday, November 4th. B. Riley Financial started coverage on Exagen in a report on Friday, September 11th. They set a “buy” rating and a $12.00 price objective for the company. BTIG Research reiterated a “buy” rating and issued a $9.00 target price on shares of Exagen in a research note on Wednesday. TD Cowen lifted their target price on Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Finally, Canaccord Genuity Group decreased their target price on Exagen from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.88.

View Our Latest Analysis on Exagen

Insider Transactions at Exagen

In related news, major shareholder Jorey Chernett bought 71,315 shares of Exagen stock in a transaction dated Wednesday, November 11th. The shares were acquired at an average cost of $5.23 per share, with a total value of $372,977.45. Following the completion of the transaction, the insider owned 2,696,940 shares in the company, valued at $14,104,996.20. The trade was a 2.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Aballi sold 34,294 shares of Exagen stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $7.87, for a total transaction of $269,893.78. Following the sale, the chief executive officer directly owned 805,540 shares of the company’s stock, valued at $6,339,599.80. This represents a 4.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders acquired a total of 100,900 shares of company stock worth $568,660 over the last 90 days. Insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new stake in Exagen during the 3rd quarter valued at $418,000. Calamos Advisors LLC purchased a new stake in shares of Exagen in the 3rd quarter worth $94,000. Penbrook Management LLC bought a new position in shares of Exagen during the 3rd quarter worth $92,000. Flputnam Investment Management Co. bought a new position in shares of Exagen during the 2nd quarter worth $1,343,000. Finally, Corient Private Wealth LP bought a new position in shares of Exagen during the 2nd quarter worth $52,000. Institutional investors own 75.25% of the company’s stock.

Exagen Stock Performance

The company has a debt-to-equity ratio of 1.73, a quick ratio of 3.18 and a current ratio of 3.46. The firm has a 50 day moving average price of $7.78 and a 200 day moving average price of $5.13.

Exagen Company Profile

(Get Free Report)

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.

Further Reading

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.